Começar
Croaking

$LXRX - Inpefa FDA Approved - Inverse H&S - BOOM BOOM ROOM

Viés de alta
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)  
Croaking  
NASDAQ:LXRX   Lexicon Pharmaceuticals, Inc.
Chart Patterns heartfailure 1pill fdaapproved jardiance farxiga inpefa lexicon Inverse Head and Shoulders oversold
2
0
chartpattern heartfailure 1pill fdaapproved jardiance farxiga inpefa lexicon inverseheadandshoulders oversold
This could be a game changer. Marketcap of Lexicon Pharm that produces Inpefa is only $538M with plenty of cash on hand. Competitor drugs Jardiance from LLY and Farxiga from AZN did over $6B and $4B revenue respectively in 2022 and expected to grow quite a bit over the next few years. Inpefa received FDA approval and was rolling out commercialization and sales at the end of June. This should be a fun ride! This is my own opinion and should not be taken as financial advice. Own your own trades.
Aviso legal

As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.